{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:04:43Z","timestamp":1771434283954,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-026-06278-4","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T10:10:13Z","timestamp":1771150213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Shayan","family":"Smani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishan","family":"Sohoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Miszczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Fazekas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawel","family":"Rajwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa A.","family":"Grimshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinaik M.","family":"Sundaresan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soum D.","family":"Lokeshwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preston C.","family":"Sprenkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyler M.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Catalona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"6278_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00261-016-0975-5","volume":"42","author":"DT Oberlin","year":"2017","unstructured":"Oberlin DT, Casalino DD, Miller FH, Meeks JJ (2017) Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer. Abdom Radiol 42:1255\u20131258","journal-title":"Abdom Radiol"},{"issue":"3","key":"6278_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.eururo.2018.05.035","volume":"75","author":"AR Padhani","year":"2019","unstructured":"Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J (2019) Prostate imaging-reporting and data system steering committee: PI-RADS v2 status update and future directions. Eur Urol 75(3):385\u2013396","journal-title":"Eur Urol"},{"issue":"6","key":"6278_CR3","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamaoncol.2024.0734","volume":"10","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Shim SR, Basile G, Baboudjian M, K\u00f3i T, Przydacz M et al (2024) Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis. JAMA Oncol 10(6):745\u2013754","journal-title":"JAMA Oncol"},{"issue":"3","key":"6278_CR4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/JU.0000000000001821","volume":"206","author":"P Rajwa","year":"2021","unstructured":"Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC et al (2021) The prognostic association of prostate MRI PI-RADS\u2122 v2 assessment category and risk of biochemical recurrence after definitive local therapy for prostate cancer: a systematic review and meta-analysis. J Urol 206(3):507\u2013516","journal-title":"J Urol"},{"issue":"2","key":"6278_CR5","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RC, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148\u2013163","journal-title":"Eur Urol"},{"issue":"5","key":"6278_CR6","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/JU.0000000000002852","volume":"208","author":"CP Filson","year":"2022","unstructured":"Filson CP, Zhu K, Huang Y, Zheng Y, Newcomb LF, Williams S et al (2022) Impact of prostate health index results for prediction of biopsy grade reclassification during active surveillance. J Urol 208(5):1037\u20131045","journal-title":"J Urol"},{"issue":"3","key":"6278_CR7","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.eururo.2016.11.017","volume":"72","author":"DW Lin","year":"2017","unstructured":"Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD et al (2017) Evaluating the four Kallikrein panel of the 4Kscore for prediction of High-grade prostate cancer in men in the Canary prostate active surveillance study. Eur Urol 72(3):448\u2013454","journal-title":"Eur Urol"},{"issue":"3","key":"6278_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","volume":"79","author":"NK Jairath","year":"2021","unstructured":"Jairath NK, Dal Pra A, Vince Jr R, Dess RT, Jackson WC, Tosoian JJ et al (2021) A systematic review of the evidence for the decipher genomic classifier in prostate cancer. Eur Urol 79(3):374\u2013383","journal-title":"Eur Urol"},{"key":"6278_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000004117","author":"KR Nandalur","year":"2024","unstructured":"Nandalur KR, Shen C, Zhao L, Al-Katib S, Lee J, Seifman B et al (2024) Association of baseline MRI PI-RADS score with prostate cancer active surveillance early biopsy reclassification: data from the michigan urological surgery improvement collaborative (MUSIC). J Urol. https:\/\/doi.org\/10.1097\/ju.0000000000004117","journal-title":"J Urol"},{"issue":"7","key":"6278_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/diagnostics10070441","volume":"10","author":"J Yu","year":"2020","unstructured":"Yu J, Fulcher AS, Winks S, Turner MA, Behl W, Ware AL et al (2020) Utilization of multiparametric MRI of prostate in patients under consideration for or already in active surveillance: correlation with imaging guided target biopsy. Diagnostics 10(7):441","journal-title":"Diagnostics"},{"issue":"4","key":"6278_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2214\/AJR.19.22196","volume":"214","author":"SH Kim","year":"2020","unstructured":"Kim SH (2020) Development and external validation of multiparametric MRI-derived nomogram to predict risk of pathologic upgrade in patients on active surveillance for prostate cancer. AJR Am J Roentgenol 214(4):825\u2013834","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"6278_CR12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.euo.2024.04.004","volume":"7","author":"M Miszczyk","year":"2024","unstructured":"Miszczyk M, Rajwa P, Fazekas T, Briganti A, Karakiewicz PI, Roupr\u00eat M et al (2024) The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024. Eur Urol Oncol 7(6):1195\u20131198","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"6278_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.juro.2015.01.077","volume":"194","author":"A Hussein","year":"2015","unstructured":"Hussein A, Welty C, Ameli N, Cowan J, Leapman M, Porten S et al (2015) Untreated Gleason grade progression on serial biopsies during prostate cancer active surveillance: clinical course and pathological outcomes. J Urol 194(1):85\u201390","journal-title":"J Urol"},{"issue":"1","key":"6278_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.juro.2015.01.102","volume":"194","author":"S Jain","year":"2015","unstructured":"Jain S, Loblaw A, Vesprini D, Zhang L, Kattan MW, Mamedov A et al (2015) Gleason upgrading with time in a large prostate cancer active surveillance cohort. J Urol 194(1):79\u201384","journal-title":"J Urol"},{"issue":"10","key":"6278_CR15","doi-asserted-by":"publisher","first-page":"7964","DOI":"10.3390\/curroncol29100630","volume":"29","author":"X Hu","year":"2022","unstructured":"Hu X, Miao J, Huang J, Qian L, Zhang D, Wei H (2022) Influence of active surveillance on Gleason score upgrade and prognosis in low-and favorable intermediate-risk prostate cancer. Curr Oncol 29(10):7964\u20137978","journal-title":"Curr Oncol"},{"key":"6278_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"6278_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","volume":"75","author":"J McGowan","year":"2016","unstructured":"McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C (2016) PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol 75:40\u201346","journal-title":"J Clin Epidemiol"},{"key":"6278_CR18","doi-asserted-by":"crossref","unstructured":"Haddaway NR, Grainger MJ, Gray CT (2021) citationchaser: an R package for forward and backward citations chasing in academic searching","DOI":"10.32614\/CRAN.package.citationchaser"},{"key":"6278_CR19","unstructured":"Yale University Harvey (2021) Cushing\/John Hay Whitney Medical, L., reference deduplicator"},{"key":"6278_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"2","key":"6278_CR21","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.urology.2014.09.060","volume":"85","author":"H Abdi","year":"2015","unstructured":"Abdi H, Pourmalek F, Zargar H, Walshe T, Harris AC, Chang SD et al (2015) Multiparametric magnetic resonance imaging enhances detection of significant tumor in patients on active surveillance for prostate cancer. Urology 85(2):423\u2013429","journal-title":"Urology"},{"issue":"3","key":"6278_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/pcan.2016.16","volume":"19","author":"JP Radtke","year":"2016","unstructured":"Radtke JP, Kuru TH, Bonekamp D, Freitag M, Wolf M, Alt C et al (2016) Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis 19(3):283\u2013291","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"6278_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.clgc.2017.10.020","volume":"16","author":"F Sanguedolce","year":"2018","unstructured":"Sanguedolce F, Petralia G, Sokhi H, Tagliabue E, Anyamene N, Hellawell G et al (2018) Baseline multiparametric MRI for selection of prostate cancer patients suitable for active surveillance: which features matter? Clin Genitourin Cancer 16(2):155\u2013163e6","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"6278_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.21037\/tau.2017.12.29","volume":"7","author":"IG Schoots","year":"2018","unstructured":"Schoots IG, Osses DF, Drost F-JH, Verbeek JF, Remmers S, van Leenders GJ et al (2018) Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease. Translational Androl Urol 7(1):132","journal-title":"Translational Androl Urol"},{"issue":"2","key":"6278_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.juro.2018.08.047","volume":"201","author":"Z Kornberg","year":"2019","unstructured":"Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S et al (2019) Genomic prostate score, PI-RADS\u2122 version 2 and progression in men with prostate cancer on active surveillance. J Urol 201(2):300\u2013307","journal-title":"J Urol"},{"issue":"2","key":"6278_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.urpr.2018.05.007","volume":"6","author":"M Van Kuiken","year":"2019","unstructured":"Van Kuiken M, Blackwell RH, Bisanz B, Joyce C, Yacoub J, Shea S et al (2019) Role of multiparametric magnetic resonance imaging prostate specific antigen density and PI-RADS\u2122 score in predicting up staging in men on active surveillance. Urol Pract 6(2):117\u2013122","journal-title":"Urol Pract"},{"issue":"4","key":"6278_CR27","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/JU.0000000000001088","volume":"204","author":"MA Liss","year":"2020","unstructured":"Liss MA, Newcomb LF, Zheng Y, Garcia MP, Filson CP, Boyer H et al (2020) Magnetic resonance imaging for the detection of high grade cancer in the Canary prostate active surveillance study. J Urol 204(4):701\u2013706","journal-title":"J Urol"},{"issue":"4","key":"6278_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.prnil.2020.05.003","volume":"8","author":"M Roscigno","year":"2020","unstructured":"Roscigno M, Stabile A, Lughezzani G, Pepe P, Dell\u2019Atti L, Naselli A et al (2020) Multiparametric magnetic resonance imaging and clinical variables: which is the best combination to predict reclassification in active surveillance patients? Prostate Int 8(4):167\u2013172","journal-title":"Prostate Int"},{"issue":"6","key":"6278_CR29","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1097\/JU.0000000000001307","volume":"204","author":"AZ Wang","year":"2020","unstructured":"Wang AZ, Oonnor LP, Yerram NK, Long L, Zeng J, Mehralivand S et al (2020) PI-RADS\u00ae category as a predictor of progression to unfavorable risk prostate cancer in men on active surveillance. J Urol 204(6):1229\u20131235","journal-title":"J Urol"},{"issue":"6","key":"6278_CR30","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1097\/JU.0000000000001186","volume":"204","author":"PE Lonergan","year":"2020","unstructured":"Lonergan PE, Washington SL III, Cowan JE, Zhao S, Nguyen HG, Shinohara K et al (2020) Risk factors for biopsy reclassification over time in men on active surveillance for early stage prostate cancer. J Urol 204(6):1216\u20131221","journal-title":"J Urol"},{"issue":"4","key":"6278_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2019.12.009","volume":"77","author":"GT Chesnut","year":"2020","unstructured":"Chesnut GT, Vertosick EA, Benfante N, Sjoberg DD, Fainberg J, Lee T et al (2020) Role of changes in magnetic resonance imaging or clinical stage in evaluation of disease progression for men with prostate cancer on active surveillance. Eur Urol 77(4):501\u2013507","journal-title":"Eur Urol"},{"issue":"6","key":"6278_CR32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JU.0000000000001313","volume":"204","author":"M Maggi","year":"2020","unstructured":"Maggi M, Cowan JE, Fasulo V, Washington SL III, Lonergan PE, Sciarra A et al (2020) The long-term risks of metastases in men on active surveillance for early stage prostate cancer. J Urol 204(6):1222\u20131228","journal-title":"J Urol"},{"issue":"5","key":"6278_CR33","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JU.0000000000000693","volume":"203","author":"A Amin","year":"2020","unstructured":"Amin A, Scheltema MJ, Shnier R, Blazevski A, Moses D, Cusick T et al (2020) The magnetic resonance imaging in active surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. J Urol 203(5):910\u2013917","journal-title":"J Urol"},{"issue":"6","key":"6278_CR34","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/bju.15033","volume":"125","author":"MK Mamawala","year":"2020","unstructured":"Mamawala MK, Meyer AR, Landis PK, Macura KJ, Epstein JI, Partin AW et al (2020) Utility of multiparametric magnetic resonance imaging in the risk stratification of men with grade group 1 prostate cancer on active surveillance. BJU Int 125(6):861\u2013866","journal-title":"BJU Int"},{"issue":"1","key":"6278_CR35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.euf.2019.05.011","volume":"7","author":"W Hsiang","year":"2021","unstructured":"Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A et al (2021) Outcomes of serial multiparametric magnetic resonance imaging and subsequent biopsy in men with low-risk prostate cancer managed with active surveillance. Eur Urol Focus 7(1):47\u201354","journal-title":"Eur Urol Focus"},{"issue":"4","key":"6278_CR36","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3348\/kjr.2020.0852","volume":"22","author":"J Salguero","year":"2020","unstructured":"Salguero J, G\u00f3mez-G\u00f3mez E, Valero-Rosa J, Carrasco-Valiente J, Mesa J, Martin C et al (2020) Role of multiparametric prostate magnetic resonance imaging before confirmatory biopsy in assessing the risk of prostate cancer progression during active surveillance. Korean J Radiol 22(4):559","journal-title":"Korean J Radiol"},{"issue":"3","key":"6278_CR37","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1016\/j.clgc.2022.01.015","volume":"20","author":"K Saout","year":"2022","unstructured":"Saout K, Zambon A, Nguyen TA, Lucas C, Payrard-Starck C, Segalen T et al (2022) Impact of multiparametric MRI and PSA density on the initial indication or the maintaining in active surveillance during follow-up in low-risk prostate cancer. Clin Genitourin Cancer 20(3):e244\u2013e252","journal-title":"Clin Genitourin Cancer"},{"key":"6278_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.euros.2021.11.006","volume":"35","author":"J Olivier","year":"2022","unstructured":"Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V et al (2022) Prostate cancer patients under active surveillance with a suspicious magnetic resonance imaging finding are at increased risk of needing treatment: results of the movember foundation\u2019s global action plan prostate cancer active surveillance (GAP3) consortium. Eur Urol Open Sci 35:59\u201367","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"6278_CR39","first-page":"e1492","volume":"5","author":"AT Beksac","year":"2022","unstructured":"Beksac AT, Ratnani P, Dovey Z, Parekh S, Falagario U, Roshandel R et al (2022) Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co\u2010variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer. Cancer Rep 5(3):e1492","journal-title":"Cancer Rep"},{"key":"6278_CR40","volume-title":"Urologic oncology: seminars and original investigations","author":"FA Mistretta","year":"2023","unstructured":"Mistretta FA, Luzzago S, Alessi S, Piccinelli M, Marvaso G, Giudice AL et al (2023) Conditional survival of patients with low-risk prostate cancer: temporal changes in active surveillance permanence over time. Urologic oncology: seminars and original investigations. Elsevier"},{"issue":"8","key":"6278_CR41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/pros.24515","volume":"83","author":"L Chamorro Castillo","year":"2023","unstructured":"Chamorro Castillo L, Garc\u00eda Morales L, Ruiz L\u00f3pez D, Salguero Segura J, Valero Rosa J, Anglada Curado F et al (2023) The role of multiparametric magnetic resonance in active surveillance of a low-risk prostate cancer cohort from clinical practice. Prostate 83(8):765\u2013772","journal-title":"Prostate"},{"issue":"6","key":"6278_CR42","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.euo.2022.03.007","volume":"5","author":"HB Luiting","year":"2022","unstructured":"Luiting HB, Remmers S, Boev\u00e9 ER, Valdagni R, Chiu PK, Semjonow A et al (2022) A multivariable approach using magnetic resonance imaging to avoid a protocol-based prostate biopsy in men on active surveillance for prostate cancer\u2014data from the international multicenter prospective PRIAS study. Eur Urol Oncol 5(6):651\u2013658","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"6278_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/aja202373","volume":"26","author":"X Wu","year":"2024","unstructured":"Wu X, Ko I-H, Hong C-L, Yee S-H, Teoh J-C, Chan S-S et al (2024) A prospective cohort of men with localized prostate cancer on active surveillance protocol in Hong Kong, China: what did we learn? Asian J Androl 26(3):245\u2013249","journal-title":"Asian J Androl"},{"issue":"1","key":"6278_CR44","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.purol.2023.09.024","volume":"34","author":"Q Bandelier","year":"2024","unstructured":"Bandelier Q, Bastide C, Charvet A-L, Leclercq L, Gondran-Tellier B, Campagna J et al (2024) Active surveillance in favorable intermediate-risk prostate cancer: a single-center experience. Fr J Urol 34(1):102537","journal-title":"Fr J Urol"},{"key":"6278_CR45","volume-title":"Urologic oncology: seminars and original investigations","author":"JW Greenberg","year":"2024","unstructured":"Greenberg JW, Koller CR, Lightfoot C, Brinkley GJ, Leinwand G, Wang J et al (2024) Annual mpMRI surveillance: PI-RADS upgrading and increasing trend correlated with patients who harbor clinically significant disease. Urologic oncology: seminars and original investigations. Elsevier"},{"key":"6278_CR46","volume-title":"Urologic oncology: seminars and original investigations","author":"M Marras","year":"2024","unstructured":"Marras M, Ellis JL, Copelan O, Naha U, Han T, Rac G et al (2024) MRI at diagnostic versus confirmatory biopsy during MRI-based active surveillance of prostate cancer. Urologic oncology: seminars and original investigations. Elsevier"},{"issue":"1","key":"6278_CR47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00345-024-04805-9","volume":"42","author":"M Duijn","year":"2024","unstructured":"Duijn M, de Reijke TM, Barwari K, Hagens MJ, Rynja SP, Immerzeel J et al (2024) The association between patient and disease characteristics, and the risk of disease progression in patients with prostate cancer on active surveillance. World J Urol 42(1):87","journal-title":"World J Urol"},{"issue":"4","key":"6278_CR48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.4111\/icu.20200601","volume":"62","author":"A Rakauskas","year":"2021","unstructured":"Rakauskas A, Tawadros T, Lucca I, Herrera F, Bourhis J, Burruni R et al (2021) Active surveillance in males with low-to intermediate-risk localized prostate cancer: a modern prospective cohort study. Invest Clin Urol 62(4):416","journal-title":"Invest Clin Urol"},{"issue":"5","key":"6278_CR49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.euo.2019.01.010","volume":"2","author":"TFW Soeterik","year":"2019","unstructured":"Soeterik TFW, van Melick HHE, Dijksman LM, Biesma DH, Witjes JA, van Basten JA (2019) Follow-up in active surveillance for prostate cancer: strict protocol adherence remains important for PRIAS-ineligible patients. Eur Urol Oncol 2(5):483\u2013489","journal-title":"Eur Urol Oncol"},{"issue":"15","key":"6278_CR50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375(15):1415\u20131424","journal-title":"N Engl J Med"},{"issue":"6","key":"6278_CR51","doi-asserted-by":"publisher","first-page":"600.e1","DOI":"10.1016\/j.urolonc.2019.12.015","volume":"38","author":"WT Turchan","year":"2020","unstructured":"Turchan WT, Kauffmann G, Patel P, Oto A, Liauw SL (2020) PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. Urol Oncol 38(6):600.e1-600.e8","journal-title":"Urol Oncol"},{"issue":"6","key":"6278_CR52","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s00345-020-03394-7","volume":"39","author":"L Bj\u00f6rnebo","year":"2021","unstructured":"Bj\u00f6rnebo L, Olsson H, Nordstr\u00f6m T, J\u00e4derling F, Gr\u00f6nberg H, Eklund M et al (2021) Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. World J Urol 39(6):1797\u20131804","journal-title":"World J Urol"},{"issue":"7","key":"6278_CR53","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3390\/cancers14071613","volume":"14","author":"M Miszczyk","year":"2022","unstructured":"Miszczyk M, Rembak-Szynkiewicz J, Magrowski \u0141, Stawiski K, Namys\u0142-Kaletka A, Napieralska A et al (2022) The prognostic value of PI-RADS score in cyberknife ultra-hypofractionated radiotherapy for localized prostate cancer. Cancers 14(7):1613","journal-title":"Cancers"},{"issue":"4","key":"6278_CR54","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/bju.12466","volume":"114","author":"J Busch","year":"2014","unstructured":"Busch J, Magheli A, Leva N, Ferrari M, Kramer J, Klopf C et al (2014) Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU Int 114(4):517\u2013521","journal-title":"BJU Int"},{"key":"6278_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.09.017","author":"T Fazekas","year":"2024","unstructured":"Fazekas T, Pallauf M, Kufel J, Miszczyk M, Tsuboi I, Matsukawa A et al (2024) Molecular correlates of prostate cancer visibility on multiparametric magnetic resonance imaging: a systematic review. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.09.017","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"6278_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","volume":"77","author":"L Klotz","year":"2020","unstructured":"Klotz L, Pond G, Loblaw A, Sugar L, Moussa M, Berman D et al (2020) Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up. Eur Urol 77(3):311\u2013317","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06278-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06278-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:11:01Z","timestamp":1771431061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06278-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6278"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06278-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"assertion":[{"value":"17 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"169"}}